Products
Samalizumab Biosimilar Monoclonal Antibody (CD200) for Research
Cat No.: GMP-Bios-ab-504
Pre-Made Samalizumab biosimilar, Whole mAb, Anti-CD200 Antibody: Anti-MRC/MOX1/MOX2/OX-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Samalizumab is a humanized monoclonal antibody designed for oncology indications.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-504-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Samalizumab biosimilar, Whole mAb, Anti-CD200 Antibody: Anti-MRC/MOX1/MOX2/OX-2 therapeutic antibody |
| INN Name | Samalizumab |
| Target | CD200 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Alexion Pharmaceuticals;The Leukemia & Lymphoma Society |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours |
| Development Tech | na |
About target - CD200
1. Protein Submitted name: OX-2 membrane glycoprotein
2. Gene CD200
3. Organism Homo sapiens (Human)
Function
